Technology Assessment Reports (TARs)
Technology Assessment Reports are detailed analyses of new medicines or medical devices. They are used to determine how cost-effective a product is.
We don't publish most of our Technology Assessment Reports (TARs) because of commercial sensitivity. We do release some reports with the commercial information removed.
TARs inform our prioritisation process.
Published Pharmac Technology Assessment Reports
Trikafta (elexacaftor, tezacaftor and ivacaftor) for cystic fibrosis
Freestyle Libre flash glucose monitoring system
Ivacaftor (Kalydeco) for cystic fibrosis with the G551D mutation
SGLT 2 inhibitors (modelled as empagliflozin)
- Appendix 1 [PDF, 164 KB]
- Appendix 2 [PDF, 125 KB]
- Appendix 3 [PDF, 61 KB]
- Appendix 4 [PDF, 64 KB]
- Appendix 5 [PDF, 178 KB]
- Appendix 6 [PDF, 511 KB]
- Appendix 7 to TAR 75c [PDF, 260 KB]
- Appendix 8 to TAR 75c [PDF, 373 KB]
- Appendix 9 to TAR 75c [PDF, 64 KB]